CpG Island Methylator Phenotype May Confer a Survival Benefit From Fluoropyrimidine-Based Adjuvant Chemotherapy on Patients With Stage II or III Colorectal Carcinomas

被引：0
|
作者：
Sung, Young Kyung
Min, Byung-Hoon
Kim, Young-Ho
Chang, Dong Kyung
Kim, Hee Cheol
Park, Cheol Keun
Kim, Kyoung-Mee
机构：
来源：
GASTROENTEROLOGY | 2010年 / 138卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
746
引用
收藏
页码：S102 / S102
页数：1
相关论文
共 50 条
  • [31] A single-centre experience of adjuvant oxaliplatin based chemotherapy in elderly stage II-III colorectal cancer patients
    Reed, H.
    Wooden, A.
    de Winton, E.
    Gangadhara, S.
    Cox, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S160 - S160
  • [32] Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients
    Huang, Yong
    Yu, Haijun
    Lei, Han
    Xie, Conghua
    Zhong, Yahua
    MEDICAL ONCOLOGY, 2014, 31 (03)
  • [33] Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer
    Artur Mezheyeuski
    Ina Hrynchyk
    Mercedes Herrera
    Mia Karlberg
    Eric Osterman
    Peter Ragnhammar
    David Edler
    Anna Portyanko
    Fredrik Ponten
    Tobias Sjöblom
    Bengt Glimelius
    Arne Östman
    British Journal of Cancer, 2019, 121 : 303 - 311
  • [34] Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer
    Mezheyeuski, Artur
    Hrynchyk, Ina
    Herrera, Mercedes
    Karlberg, Mia
    Osterman, Eric
    Ragnhammar, Peter
    Edler, David
    Portyanko, Anna
    Ponten, Fredrik
    Sjoblom, Tobias
    Glimelius, Bengt
    Ostman, Arne
    BRITISH JOURNAL OF CANCER, 2019, 121 (04) : 303 - 311
  • [35] Prognostic model for predicting the survival benefit of adjuvant chemotherapy for elderly patients with stage II colon cancer: a population-based study
    Yu, Guanhua
    Wei, Ran
    Liu, Hengchang
    Liu, Yixiao
    Guan, Xu
    Wang, Xishan
    Jiang, Zheng
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2024, 33 (02) : 105 - 114
  • [36] No Survival Benefit From Postoperative Adjuvant Chemotherapy After D2 Radical Resection for the Patients With Stage II Gastric Cancer
    Chen, Shi
    Chen, Ying-Bo
    Zhou, Zhi-Wei
    Li, Wei
    Sun, Xiao-Wei
    Xu, Da-Zhi
    Li, Yuan-Fang
    Guan, Yuan-Xiang
    Feng, Xing-Yu
    Zhan, You-Qing
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (03): : 309 - 313
  • [37] Multi-center evaluation of machine learning-based radiomic model in predicting disease free survival and adjuvant chemotherapy benefit in stage II colorectal cancer patients
    Hui Zhu
    Muni Hu
    Yanru Ma
    Xun Yao
    Xiaozhu Lin
    Menglei Li
    Yue Li
    Zhiyuan Wu
    Debing Shi
    Tong Tong
    Haoyan Chen
    Cancer Imaging, 23
  • [38] Multi-center evaluation of machine learning-based radiomic model in predicting disease free survival and adjuvant chemotherapy benefit in stage II colorectal cancer patients
    Zhu, Hui
    Hu, Muni
    Ma, Yanru
    Yao, Xun
    Lin, Xiaozhu
    Li, Menglei
    Li, Yue
    Wu, Zhiyuan
    Shi, Debing
    Tong, Tong
    Chen, Haoyan
    CANCER IMAGING, 2023, 23 (01)
  • [39] Selecting patients with stage II/III colorectal cancer for 5-fluorouracil-based adjuvant chemotherapy using proteomic analysis.
    Yan, Dongyao
    Hong, Ji Hyung
    Lee, Hee Yeon
    Byun, Jae Ho
    Cecchi, Fabiola
    Tian, Yuan
    Schwartz, Sarit
    An, Eunkyung
    Hembrough, Todd A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [40] Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study
    Alwers, Elizabeth
    Jansen, Lina
    Blaeker, Hendrik
    Kloor, Matthias
    Tagscherer, Katrin E.
    Roth, Wilfried
    Boakye, Daniel
    Herpel, Esther
    Gruellich, Carsten
    Chang-Claude, Jenny
    Brenner, Hermann
    Hoffmeister, Michael
    MOLECULAR ONCOLOGY, 2020, 14 (02) : 363 - 372
12345